Clinical Trials Logo
  1. Home
  2. Early Gastric Cancer
  3. NCT01774266
  4. Details
NCT01774266 Clinical Trial

Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer

Early Gastric Cancer Clinical Trial

— DEMRAC  

Official title:
Screening and Triage Test for Early Detection of Gastric Cancer

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01774266
Other study ID # D09I1137
Secondary ID 11-156
Status Recruiting
Phase N/A
First received January 19, 2013
Last updated May 30, 2013
Start date September 2012
Est. completion date March 2014

Study information
Verified date May 2013
Source Pontificia Universidad Catolica de Chile
Contact Alejandro H. Corvalan, M.D.
Phone +56-02-354-8289
Email corvalan@med.puc.cl
Is FDA regulated No
Health authority Chile: Institutional Review Board
Study type Observational

Clinical Trial Summary

In this proposal the investigators aim to develop a commercial kit to be used in primary screening and non-invasive triage for early detection of gastric cancer. This kit will be cost-effective and more accessible to the general population. In addition, the investigators would like to expand our current patent already submitted to INAPI (National Institute for Intellectual Property) and propose royalties to biomedical diagnostic companies for the use of our product at international level.

Description:

Gastric cancer is the first cause of death in Chile and the second worldwide. Currently, no screening methods are available for early detection of gastric cancer at population level. The only available test is serum levels of pepsinogen I/II for gastric atrophy, a precursor lesion only for intestinal type with low risk to progress to gastric cancer. The investigators' previous work, supported by FONDECYT (National Council for Research and Technology) and FONIS (National Council for Research and Development of Human Health) both from the Government of Chile led us to discover a potential biomarker for early detection of gastric cancer, Reprimo, a tumor suppressor gene related to p53 in the arrest of G2-M of the cell cycle (Clin Cancer Res. 2008;14:6264-9). Here, the investigators propose to evaluate plasmatic detection of Reprimo in conjunction with gastric atrophy markers and H.pylori detection to establish a novel screening and triage strategy for early detection of gastric cancer. The aims are i) to determine sensitivity and specificity for Reprimo in the detection of gastric cancer in a high-risk population evaluated by upper gastrointestinal endoscopy (1,000 males, 30-74 y.o. low income, symptomatic or asymptomatic) and ii) to characterize at clinical, pathological and molecular level cases of gastric cancer identified and non-identified by direct detection of Reprimo along with atrophy, H.pylori and clinical markers. With this information, the investigators will develop an algorithm for screening and triage evaluating predictive values of plasmatic detection of Reprimo versus atrophy & H.pylori detection and clinical data in a general population (3,000 male/female, 40-70 y.o.) from a high-risk area for gastric cancer in Chile. In this step the investigators will evaluate also acceptability, efficacy and efficiency of the proposed algorithm. In this proposal the investigators aim to develop a commercial kit to be used in primary screening and non-invasive triage for early detection of gastric cancer. This kit will be cost-effective and more accessible to the general population. In addition, the investigators would like to expand the investigators' current patent already submitted to INAPI and propose royalties to biomedical diagnostic companies for the use of the investigators' product at international level.

Recruitment information / eligibility
Status Recruiting
Enrollment 3000
Est. completion date March 2014
Est. primary completion date December 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

- Male or Female

- Age 40-70 y.o.

Exclusion Criteria:

- Gastric Cancer

- Dyspepsia

- Bleeding disorders

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Chile Hospital Santa Rosa de Molina Molina Region del Maule

Sponsors (4)
Lead Sponsor Collaborator
Pontificia Universidad Catolica de Chile Hoffmann-La Roche, Ministerio de Salud de Chile, Red Salud UC

Country where clinical trial is conducted

Chile, 

References & Publications (1)

Bernal C, Aguayo F, Villarroel C, Vargas M, Díaz I, Ossandon FJ, Santibáñez E, Palma M, Aravena E, Barrientos C, Corvalan AH. Reprimo as a potential biomarker for early detection in gastric cancer. Clin Cancer Res. 2008 Oct 1;14(19):6264-9. doi: 10.1158/1078-0432.CCR-07-4522. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Other Detection of H.pylori and gastric atrophy The rate of H.pylori detection and gastric atrophy based on serum levels of H.pylori and Pepsinogens I/II ratio. 2 years No
Primary Early detection of gastric cancer Increase the frequency of early detection rate of gastric cancer 2 years No
Secondary Monitoring progression of disease In the case in which diagnoses of gastric cancer will be made, the result of treatment will be measure 2 years No
See also
  Status Clinical Trial Phase
Terminated NCT04977401 - EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection N/A
Not yet recruiting NCT04083573 - Comparison of Diagnostic Performance of Medical Monitor and Medical Augmented Reality Glasses in Endoscopy: Observation Study
Completed NCT02504164 - Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection N/A
Completed NCT01435525 - Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation N/A
Completed NCT01921283 - Monitored Anesthesia Care With Propofol Plus Remifentanil During Endoscopic Submucosal Dissection: Evaluation of Bispectral Index Monitoring N/A
Completed NCT01364324 - Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Recruiting NCT03837301 - Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2) Phase 2
Recruiting NCT05269056 - Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics
Not yet recruiting NCT03632746 - Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients
Completed NCT01938326 - Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG) N/A
Recruiting NCT04602689 - Fibrin Glue After ESD for High Risk Patients of Bleeding N/A
Recruiting NCT05291728 - Screening for Early Gastric Cancer in Shaanxi Province
Not yet recruiting NCT06152783 - Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study
Completed NCT02189226 - Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection N/A
Completed NCT04602299 - Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors N/A
Completed NCT02562976 - OLGA Stage is More Appropriate in Predicting Early Gastric Cancer N/A
Recruiting NCT01132469 - Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer N/A
Completed NCT03136354 - Prospective Randomized Trial Comparing Endoscopic Submucosal Dissection Against Laparoscopic Assisted Gastrectomy for Treatment of Early Gastric Cancer N/A
Completed NCT02216110 - Endoscopic Submucosal Dissection Versus Gastrectomy N/A
Recruiting NCT04411589 - The Diagnostic Ability of White Light Endoscopy and Magnifying Endoscopy With Optical Enhancement System N/A

External Links